Form S-3ASR Cogent Biosciences, Inc.
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 10/27/2026
Go back to Form S-3ASR Cogent Biosciences, Inc.
November 10, 2025 1:18 PM EST
Leerink Partners analyst Andrew Berens raised the price target on Cogent (NASDAQ: COGT) to $50.00 (from $18.00) while maintaining a Outperform rating.
The analyst comments "This morning, COGT announced topline results for the Ph 3 PEAK trial and hosted a conference call. As a reminder, PEAK evaluated the KIT inhibitor bezuclastinib (bezu) in combination with sunitinib vs sunitinib monotherapy in patients with gastrointerstinal stromal tumors (GIST) after progression on the 1L therapy imatinib. We view the results obtained in the 2L as offering unprecedented efficacy... More
November 10, 2025 10:54 AM EST
Stifel analyst Laura Prendergast upgraded Cogent (NASDAQ: COGT) from Hold to Buy with a price target of $40.00 (from $16.00).
The analyst comments "Today, COGT reported overwhelmingly positive results in the Ph3 PEAK study of bezuclastinib plus sunitinib vs. sunitinib alone in 2L GIST... More
November 7, 2025 4:53 PM EST
Cogent Biosciences (NASDAQ: COGT) has filed mixed shelf of:
COMMON STOCK
PREFERRED STOCK
DEBT SECURITIES
WARRANTS
UNITS
...
More
